Table 6.
Bortezomib use in renal and cutaneous autoimmune diseases.
| Study type | Autoimmune disease | Study population | N | Comments | References |
|---|---|---|---|---|---|
| Case series | IgA nephropathy | Adult (35 ± 12 years) | 8 | • Bortezomib 1.3 mg/sqm IV for four doses over a 2-week cycle • Response: CR (N = 3), PR (N = 1), NR (N = 3), unknown (N = 1) • Toxicity: G1 thrombocytopenia (N = 2) |
Hartono et al. 69 |
| Case report | IgA vasculitis related to IgA smoldering myeloma | Adult (35 years) | 1 | • Bortezomib + lenalidomide + dexamethasone • Response: CR after two courses and disappearance of the monoclonal protein (off-therapy follow-up: 10 months) • No toxicity |
Paule et al. 70 |
| Case report | Nephrotic syndrome in idiopathic membranous nephropathy | Adult (58 years) | 1 | • Bortezomib 1.6 mg on days 1, 4, 8 and 11 + ramipril + steroid • Complete remission • No toxicity |
Hartono et al. 71 |
| Case report | Nephrotic syndrome in membranous nephropathy with light chain restriction | Adult (40 years) | 1 | • Bortezomib 1.3 mg/sqm on days 1, 4, 8 and 11 + thalidomide + dexamethasone for six 28-day cycles • Response: progressive rise in serum creatinine from the second year |
Ramachandran et al. 72 |
| Case report | Microscopic polyangiitis | Adult (58 years) | 1 | • Bortezomib 1.3 mg/sqm/week for four cycles • Response: prolonged remission • No toxicity |
Novikov et al. 73 |
| Case report | IgA pemphigus and MGUS | Adult (61 years) | 1 | • Bortezomib 1.3 mg/sqm on days 1, 4, 8 and 15 + cyclophosphamide + dexamethasone • Response: CR • No toxicity |
Adam et al. 74 |
| Case report | MM and IgA pemphigus | Adult (50 years) | 1 | • Bortezomib 1.3 mg/sqm IV on days 1, 4, 8 and 15 + cyclophosphamide + dexamethasone (28-day cycles) for six cycles • Response: rapid skin response; the complete skin and hematologic remission lasted 18 months • Toxicity: neuropathic pain and weakness leading to suspension after six cycles |
Szturz et al. 75 |
CR, complete remission; Ig, immunoglobulins; IV, intravenous; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; NR, non-response; PR, partial remission.